Search company, investor...

Founded Year

2015

Stage

Series B - II | Alive

Total Raised

$106.3M

Last Raised

$30M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-11 points in the past 30 days

About Holmusk

Holmusk is a data analytics and health technology company focused on behavioral health. The company offers a real-world evidence platform that leverages AI-powered analytics and digital solutions to improve research and care in behavioral health. Holmusk's main services include providing access to a comprehensive behavioral health database, advanced data analytics software, and an electronic health records platform designed for psychiatry practices. It was founded in 2015 and is based in New York, New York.

Headquarters Location

54 Thompson Street 4th Floor

New York, New York, 10012,

United States

917-776-3057

Loading...

Holmusk's Product Videos

ESPs containing Holmusk

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Health Data & Analytics

The real-world data providers market offers a variety of value propositions to the pharmaceutical industry, drug labs, and healthcare organizations. It provides access to diverse patient populations, longitudinal real-world data, and patient-powered or EHR-powered controls that can replicate real-world scenarios. This can help shorten drug development timelines, reduce patient recruitment burdens …

Holmusk named as Highflier among 15 other companies, including TriNetX, Truveta, and Syapse.

Holmusk's Products & Differentiators

    NeuroBlu Database

    The NeuroBlu database serves as the healthcare and pharmaceutical industry’s leading source for real-world behavioral health data. The database contains de-identified, longitudinal EHR data from over 1 million patients collected over more than 20 years from geographically diverse clinics across the U.S. The rapidly growing database includes data on patient diagnosis, treatment, hospitalization, and demographics, as well as nuanced information about external stressors, progress, treatment side effects, and more. NeuroBlu data fuel research for behavioral health conditions such as major depressive disorder, bipolar disorder, PTSD, ADHD, schizophrenia, substance-related disorders, and many others. The data have been used for a range of purposes, from assisting with early-stage drug research to driving public health impact.

Loading...

Expert Collections containing Holmusk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Holmusk is included in 2 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

14,769 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.

D

Digital Health

11,068 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Latest Holmusk News

Holmusk, Veradigm Mark New Milestone in Data Enrichment Partnership

Jul 29, 2024

Holmusk, Veradigm Mark New Milestone in Data Enrichment Partnership Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression Holmusk, a leading global mental health real-world evidence company, and Veradigm® (OTCMKTS: MDRX), a leading healthcare data and technology solutions provider, today announced that they have reached a new data enrichment milestone in their strategic collaboration. This collaboration, announced last year, draws upon the strengths of each company to drive innovation and generate real-world evidence designed to accelerate mental health research and care. Veradigm also led Holmusk’s 2023 Series B funding round as part of this collaboration. To reach this milestone, Holmusk and Veradigm collaborated to identify additional insights to assess disorder progression within Veradigm Network EHR data, enriching millions of patient profiles with sufficient data points for inclusion in real-world data investigations. Holmusk worked with Veradigm’s Medical Informatics team to transform semi-structured data captured at the point-of-care into analyzable, structured data. This information provides key insights into how a patient’s disorder evolves throughout the clinical care journey. A high density of psychometric scales enables leaders in research, government, healthcare, and academia to more granularly assess treatment effectiveness, care patterns and gaps, and disorder progression. “As a psychiatrist, investigator, and professor, access to outcome-rich data like these is invaluable when conducting research on the identification, characterization, and treatment of those with severe psychiatric disorders. This milestone marks a turning point in our expertise and ability to harness outcome measures at scale and at a level of granularity that is all too often missing from real-word data.” – Dr. Christoph Correll, Professor of Psychiatry, Zucker School of Medicine, Hofstra/Northwell; Professor and Chair, Department of Child and Adolescent Psychiatry, Charité University Medicine; Scientific Advisor, Holmusk These patient-level data are now available in NeuroBlu Data, the largest NLP-enriched real-world dataset for mental health. Holmusk continues to deepen the dataset’s value as the leading global source for mental health insights from clinical care through strategic partnerships. “Holmusk’s collaboration with Veradigm is based on our shared vision to transform evidence generation for research and clinical practice with real-world data. This milestone has uncovered a significant volume of measures of mental health progression, enriching NeuroBlu Data and the ability to deliver precision neuroscience. We are continuing to build upon this unparalleled source of rich, real-world data to address the evidence gap in mental health and positively impact patient outcomes.” – Nawal Roy, Founder & CEO of Holmusk “By combining Holmusk’s global leadership in clinical insights for mental health with Veradigm’s direct access, network reach, and technical expertise for enhancing EHR-derived data, we have uncovered these underutilized data points, enhancing the understanding of treatment strategies for mental health conditions. Together, we’ve tapped into a wealth of data that is key to advancing patient care in mental health.” – Tom Langan, Interim CEO, Veradigm Through this strategic collaboration, Holmusk and Veradigm will continue to leverage their collective expertise to optimize data availability and standardization to support robust real-world evidence generation for mental health. previous post

Holmusk Frequently Asked Questions (FAQ)

  • When was Holmusk founded?

    Holmusk was founded in 2015.

  • Where is Holmusk's headquarters?

    Holmusk's headquarters is located at 54 Thompson Street, New York.

  • What is Holmusk's latest funding round?

    Holmusk's latest funding round is Series B - II.

  • How much did Holmusk raise?

    Holmusk raised a total of $106.3M.

  • Who are the investors of Holmusk?

    Investors of Holmusk include Veradigm, Heritas Capital, Health Catalyst Capital Management, dRx Capital, Northwell Holdings & Ventures and 7 more.

  • Who are Holmusk's competitors?

    Competitors of Holmusk include Feel Therapeutics, Tempus, TriNetX, NeuroFlow, Owkin and 7 more.

  • What products does Holmusk offer?

    Holmusk's products include NeuroBlu Database and 1 more.

Loading...

Compare Holmusk to Competitors

Evidation Logo
Evidation

Evidation focuses on harnessing real-world health data to measure and improve health outcomes. The company offers a digital health measurement and engagement platform that utilizes data science and machine learning to provide health guidance, treatments, and tools. Evidation primarily serves life sciences companies, government bodies, and academic institutions. It was founded in 2012 and is based in San Mateo, California.

Aetion Logo
Aetion

Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.

V
Verantos

Verantos is a company that focuses on generating high-validity real-world evidence in the life sciences sector. The company offers a platform that integrates various real-world data sources and uses artificial intelligence to generate evidence with high accuracy, completeness, and traceability. This evidence is used to accelerate clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across all therapeutic areas. It was founded in 2015 and is based in Menlo Park, California.

Owkin Logo
Owkin

Owkin operates as an artificial intelligence (AI)-based biotechnology company. It utilizes AI to enhance the process of finding suitable treatments for patients. The company's main services include the use of AI to identify new treatments, accelerate clinical trials, and build diagnostic tools. It enables researchers in hospitals, universities, and the biopharmaceutical industry to understand how drug efficacy varies for the improvement of drug development. Its services primarily cater to the biopharmaceutical and academic research sectors. It was founded in 2016 and is based in New York, New York.

Atropos Health Logo
Atropos Health

Atropos Health specializes in transforming healthcare data into actionable evidence for the healthcare and life sciences sectors. The company offers solutions that support clinical decisions, optimize health systems, and accelerate clinical research by leveraging a vast network of patient records and analytics tools. Atropos Health primarily serves the healthcare industry, including health systems and life science companies, by providing insights for formulary design, quality improvement programs, and clinical trial emulations. It was founded in 2019 and is based in New York, New York.

Datavant Logo
Datavant

Datavant operates as a company focused on health data connectivity in the healthcare industry. It offers services that securely and compliantly connect patient-level health data, providing solutions for data and analytics, life sciences, providers, government agencies, research networks, and health plans. Its primary customers are organizations within the healthcare sector. The company was founded in 2017 and is based in San Francisco, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.